Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 13/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 12/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6531342 | 0.87 | ADRB3 (0.52) | ADRB3ADRB1ALDH1A1ADRB2MEN1 | |
| SCHEMBL6531335 | 0.87 | ADRB3 (0.52) | ADRB3ADRB1ALDH1A1ADRB2MEN1 | |
| SCHEMBL7687852 | 0.86 | ADRB3 (0.59) | ADRB3ADRB1ADRB2KMT2A | |
| SCHEMBL6479253 | 0.86 | ADRB3 (0.56) | ADRB3ADRB1ALDH1A1ADRB2MEN1 | |
| SCHEMBL6479255 | 0.86 | ADRB3 (0.56) | ADRB3ADRB1ALDH1A1ADRB2MEN1 | |
| SCHEMBL7691890 | 0.83 | ADRB3 (0.51) | ADRB3ADRB1ADRB2PDGFRAKDR | |
| SCHEMBL6539169 | 0.83 | ADRB1 (0.72) | ADRB3ADRB1ALDH1A1PKMMAPK1 | |
| SCHEMBL6479456 | 0.81 | ADRB3 (0.58) | ADRB3ADRB1ADRB2PDGFRA | |
| SCHEMBL6479461 | 0.81 | ADRB3 (0.58) | ADRB3ADRB1ADRB2PDGFRA | |
| SCHEMBL6533443 | 0.81 | ADRB3 (0.52) | ADRB3ADRB1ALDH1A1MAPK1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
| EP-1140849-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040560-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | ADRB3 3/4885ADRB1 1/4885ALDH1A1 275/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | ADRB3 3/4885ADRB1 2/4885ALDH1A1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.